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3a). 3,126 primer pairs generating amplicons of ~100bp were designed to cover all coding areas of the genes concerned.
All designs covered >95% of the target region. All probe sets were evaluated in silico and the TargetSeq probe set was subsequently redesigned, allowing for up to 8 close matches between the probe and build hg19 of the human genome (as opposed to the default setting of 5).
Libraries were generated according to the manufacturer's protocol. Briefly, multiplex PCR was performed with the Ion Ampliseq library kit 2.0 using 10 ng DNA for each of two primer pools, which were combined after target amplification. IonXpress-barcoded adapters were attached to the amplicons by ligation. The libraries were purified using Agencourt AMPure XP magnetic beads (Beckman Coulter Ltd, High Wycombe, UK) and amplified using adapter primers. The amplified libraries were purified again and quantified on an Agilent 2100 Bioanalyzer using the High Sensitivity DNA kit (Agilent Technologies, Stockport, UK). Library templates for sequencing were prepared by emulsion PCR on the One Touch 2 instrument and loaded onto 318 semiconductor chips and the Ion Torrent PGM™ sequencer 7 . One tumour-normal pair was run per chip, with a ratio of 10:1, in order to obtain an average coverage of 1000X for tumour and 100X for normal samples. 99% of amplicons within both the tumour and normal data met these criteria. Overall, 597 tumour-normal pairs were sequenced.
Mutation quality control
Somatic variants were called by Ion Reporter Software v4.0 (Thermo Fisher) using the default Tumour-Normal workflow. Filtering out of low quality variants was performed in three stages. Firstly, variants were removed if marked as low confidence by Ion Reporter (allele frequencies <10% in both tumour and normal or low coverage in the normal) or were CNVs, off-target variants, or indels with more than one alternative variant.
Secondly, in order to remove artefacts, including deamination that results in C:G>T:A substitutions 8 , a predictive regression model with true or false positive mutation as the outcome was built, based on a subset of variants classified with high confidence as true and false positives. True positives were identified from main mutation hotspots in 10 CRC driver genes (Supp. Table 6 ) and false positives were defined heuristically as those non-synonymous variants found more frequently than BRAF V600E (Supp . Table 7) , the most common single nucleotide change in CRC 9 . Predictive variables in the model included number of reads supporting the variant, allelic frequency in the tumour, allelic frequency in the normal and a P-value for quality provided by Ion Reporter (Supp. Table 8 ). All four variables were independently associated with the outcome. Accordingly, coefficients and constant were applied in the standard logistic regression model to all reported variants with the following formula:
ln(P/1-P) = 0 + 1X1 + 2X2 +…+ kXK where P is the probability that a variant is a true positive and K in this instance=1-4. A ROC curve was then plotted (Supp. Figure 2 ) where P≥0.39 gave the highest number of correctly classified variants (95.4%), corresponding to high predicted sensitivity (96.7%) and specificity (94.5%). Variants with P<0.39 were therefore excluded from analysis.
Thirdly, in order to take a conservative approach, we excluded cancers with very high levels of deamination and hence high levels of false-positive mutations despite the above variant filtering. In a plot of total mutation burden against proportion of C:G>T:A changes in both our data and CRC TGCA data, we applied a heuristic cut-off (Supp. Figure 4) and removed 86 cancers (14.4%).
We then performed three different analyses to check the quality of our mutations. Firstly, we found mutation spectra resembling the three main signatures reported for CRC linked to aging, MSI and POLE (signatures 1, 6 and 10 respectively) in the overall CRC sample set 10 (Supp. Figure 5) . Secondly, the levels of hypermutation for SNVs and indels according to MSI and POLE status were in agreement with the literature 9,11 (Supp. Table 11 and Supp. Figure 6 ).
Finally, our mutations in KRAS and BRAF from Sanger sequencing and Ion Torrent showed 97% concordant results. In summary, all three tests suggested that a high quality set of mutations remained after filtering using our sequencing and subsequent downstream pipeline analysis.
Mutation burden
The mutation burden of each cancer was measured as the total number of somatic non-synonymous variants and coding indels affecting any gene in the panel, after applying quality control. This measure of burden was very strongly correlated with the number of all mutations, including synonymous and extra-exonic changes (r 2 =0.98) (Supp Figure   11 ). Both measures gave equivalent results in the analyses (data not shown). Quartiles were calculated such that ties (burden values lying on a quartile boundary) were assigned to the same quartile, specifically to the quartile with the larger number of cancers with that burden.
Driver mutation assignment
In order to classify variants as putative driver mutations, we first identified genes in which recurrent pathogenic mutations have recently been reported in a pan-cancer analysis 12 , or are known to be bona fide tumour suppressors from the wider literature. From the resulting 25 genes, mutations were selected as drivers as follows: 1-nonsense, frameshift or splice site mutations in tumour suppressor genes; 2-hotspot missense reported as pathogenic according to Chang et al 12 , including across homologues (e.g. Ras genes); 3-mutations predisposing to colorectal cancer according to ClinVar (rated with at least 2 stars and manually curated); 4-additional TP53 mutations showing less than 50% expression in yeast compared to wildtype in all assays according to the IARC database 13 (Supp. Table 9 ). Exploratory analyses with or without these few mutations gave extremely similar results (data not shown). Any driver mutation with a variant allele frequency (VAF) below 0.1 with a minimum read depth of 100X, from a cancer with a putative clonal mutation peak at VAF>0·25 was regarded as at low allele frequency and hence potentially sub-clonal. Such mutations were analysed for clonal diversity.
Association analysis
Methods for analysis of association (regression, clustering and Bayesian networks) have already been reported 14 . Briefly, pairwise associations for categorical and continuous variables were assessed using Fisher's exact test and Student's ttest, respectively. To control for multiple hypothesis testing, P values were corrected with the false discovery rate control proposed by Benjamini and Hochberg and the obtained q value was considered significant if <0.05. Multivariate analysis was performed using both reverse and forward stepwise logistic regression (or linear regression for age and cancer differentiation) and P < 0.05 considered significant.
Additionally, cluster analyses were performed, with the aim of finding robust associations and pathways using more than one method. Unsupervised hierarchical agglomerative clustering analysis was performed with Ward's method, in which the distance between two clusters is the increase in variance for the cluster being merged, and a heat map was created. To build a model of the relationships between variables to identify which variables depend on which others and which are conditionally independent, a static Bayesian network analysis was done. This provides heuristic search strategies, consisting of a proposer for a new network, a cycle checker which investigates proposed networks for cycles, an evaluator which calculates the scores of proposed networks, and a decider to accept or not a proposed network. All analyses were performed with STATA, R or Banjo.
Molecular screening in Australian cohort
Tissue and DNA were stored at -80ᵒC and -20ᵒC respectively. Targeted sequencing was performed with custom amplicon panels against 113 genes designed for use with the HaloPlex™ Target Enrichment System (Supp . Table 3b ).
Probes were designed using maximum stringency optimised criteria and only genes with >90% probe coverage were included in the final design. The final design was optimised for a read length of 100 bp. A total of 33,942 amplicons were sequenced, with total target coverage of 99·2% across the gene panel. Sample libraries were prepared using the automated Bravo liquid handling platforms optimised for HaloPlex™ Target enrichment in a 96 well format. This system was optimised for successful digestion, library indexing, and purification from a total input 225ng of DNA. The final library was sequenced on the NextSeq 500 (Illumina, USA) using the NextSeq500/550 V2 High Output Kit-150 cycles (Illumina, USA, FC-404-2002) as per manufacturer's instructions. Each sample was sequenced at ~2 million reads per sample. Both tumour and normal samples were sequenced to an average coverage of greater than 1000 reads, in all cases >100-fold coverage of >95% of targeted regions was achieved. Mutations were called using a modified GATK "Best Practice" pipeline, removing the "removal of duplication" step. Somatic mutations were identified by subtracting matched normal variants from those identified in the tumour. Mutation spectra (Supp. Figure 9 ) and levels of hypermutation according to MSI and POLE status (Supp. Figure 10 ) were in agreement with the literature 4, 9, 10 .
MSI was analysed with tumour and matched normal DNA that was polymerase chain reaction (PCR)-amplified for the Bethesda panel of microsatellite markers (BAT25, BAT26, D2S123, D5S346, D17S250) using fluorescently-labelled primers 1 . Reaction products were analysed on a 3130xl Genetic Analyzer (Applied Biosystems). MSI+ was diagnosed if instability was evident at two or more markers.
All patients of the cohort were characterised for KRAS (codons 12, 13), TP53 (exons 4-9) and BRAF codon 600 mutations based on Sanger sequencing at the Ludwig Institute Parkville, Melbourne. Tumours were microdissected from the originating FFPE blocks. Hematoxylin and eosin-stained sections were reviewed by an anatomical pathologist and macrodissected in areas comprising greater than 60% neoplastic cells. Genomic DNA was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen) and amplified using PCR (Supp. Table 5 ). Direct DNA sequencing was conducted using BigDye Terminator v3.1 Ready Reaction Mix (Applied Biosystems). Reaction products were run on 3730xl DNA Analyzers (Applied Biosystems). Mutations detected were confirmed as somatic by bidirectional resequencing of new PCR products from tumour and matched normal DNA or cell line DNA. Primer details are available from authors.
Samples with indeterminate sequencing traces on first analysis were subjected to repeat PCR and sequencing.
Survival analyses
Time-to-event analysis was performed for relapse-free survival (RFS) right-truncated at 5 years, as biologically this is the most relevant endpoint. RFS was defined as time from surgery to the first confirmed relapse, with censoring done when a patient died from causes unrelated to cancer or was alive without recurrence at last contact. Kaplan-Meier survival curves were generated and univariable survival distributions compared. Cox proportional hazards models were used to estimate survival distributions and hazard ratios and multivariate analyses included T stage, N stage, treatment arm and MSI where relevant. All survival analyses were two-sided and considered significant if P < 0.05. These were conducted with STATA. In all cases, we compared biomarker associations between the two arms of QUASAR2, and no significant differences were found (details not shown). Equivalent analyses were performed for the Australian cohort. Prognostic models were compared by nested likelihood ratio test and robustness was assessed by repeating the analysis randomly omitting 10% of cases each time. Note that in statistical analyses with the Australian cohort, BRAF mutations other than V600E in QUASAR2 were not taken as pathogenic as they had not been screened.
Analyses with or without these few mutations gave extremely similar results (data not shown). All molecular assays were performed blinded to clinico-pathological and survival data. Samples with missing data in any given multivariable model were not included (Supp. Table 2 and Supp. Figure 1 ).
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Supplementary Tables   Supplementary Table 1 . Previous studies of molecular prognostic markers in CRC that comprised >400 patients [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Where multivariable analysis was performed, those results are reported, although use of co-variables varies among studies. Some studies may be sub-sets of others. Only nominally significant associations are reported: *=P<0.05, **=P<0.01, ***=P<0.001 (all uncorrected values). MSI does not include "MSI-low" but may be variably defined. MMR=presence (P) or deficiency (D) of mismatch repair proteins, principally MLH1. $ No P value reported; ^Compared with 3 other subtypes with similar trends ; # HR>1 denotes longer survival in that study. DDR2  IDH2  PTEN  WT1  AKT1  EGFR  JAK2  PTPN11  XRCC2  ALK  ERBB2  JAK3  RAD51  APC  ERBB4  KDR  RB1  AR  ERCC1  KIT  RET  ATM  EZH2  KRAS  RRM1  ATRX  FANCA  MAP2K1  RUNX1  AURKA  FANCC  MAP2K2  SMAD4  AURKB  FBXW7  MAP3K1  SMARCB1  AURKC  FGFR1  MDM2  SMO  BRAF  FGFR2  MET  SRC  BRCA1  FGFR3  MLH1  STK11  BRCA2  FLT3  MTOR  TET2  C11orf30  GNAS  N4BP2L2  TLR4  CCND1  HDAC1  NF1  TNKS1  CDH1  HDAC2  NOTCH1  TNKS2  CDKN2A  HDAC3  NPM1  TP53  CSF1R  HNF1A  NRAS  TTLL5  CTNNB1  HRAS  PDGFRA  UGT1A1  CYP2D6  IDH1  PIK3CA ACVR2A  CDC42EP1 GNRH2  MESP1  PTEN  TGIF1  ADCK5  CHD6  GPX1  MICALCL  PTPLA  TIAM1  ADM2  CNOT2  GRIN3B  KMT2D  RALY  TMEM184A  ADRA2B  CREBBP  GSPT1  MUC6  RAVER1 TMPRSS13  AP3S1  CTNNB1  HDGFRP2  MYADML2 RBM5  TP53  APC  CTSA  HNRNPL  NEUROG3 RIN3  TRRAP  ASH1L  DBR1  HRCT1  NRAS  RNF43  TTLL11  ATM  DIAPH1  HTT  OVGP1  RNPC3  TYRO3  ATN1  DRD4  IRF5  PABPC1  RPL14  WRAP53  ATXN1  ECHS1  KANK3  PAK2  SAFB2  ZFHX3  AXIN2  ELF3  KDM6B  PCGF6  SLC5A10 ZFP36L2  B2M  EP300  KIAA0040  PHF2  SMAD4  ZNF787  BAIAP2L2 EP400  KMT2C  PHF21A  SOX9  ZNF880  BCL9L  ERBB3  KRAS  PIK3C2B  SPERT  BZRAP1  FAM171B  KRTAP5-5  PIK3CA  SPHK1  C21ORF58 FAM46A  LATS2  PLIN4  SPPL2B  C6ORF223 FAT1  MAFA  PPM1E  SRCAP  CACNA1B FBXW7  MAL2  PRDM2  TBP  CD58  FNBP4  MED31  PRIM2  TCF7L2  CD7  GLTPD2  MEF2A  PRX  TDG Supplementary Table 4 . Prognostic analyses performed and reported in this study. The endpoint of all analyses was relapse-free survival (RFS). *GNAS mutation was not available in the Australia cohort. Stepwise multivariable regression analysis searching for associations between clinico-pathological-molecular variables. # and * predicted perfect or near-perfect success and failure respectively and hence were formally dropped from the analysis, but are shown here for completeness' sake. 
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Prognostic Analysis
These were chosen as high-confidence somatic mutations for use in the regression model to clean false positive variants from the Ion Torrent sequencing. These are all very well described hotspots in CRC driver genes.
